rapport therapeutics inc - RAPP
RAPP
Close Chg Chg %
22.19 1.01 4.55%
Open Market
23.20
+1.01 (4.55%)
Volume: 37.40K
Last Updated:
Nov 21, 2024, 1:29 PM EDT
Company Overview: rapport therapeutics inc - RAPP
RAPP Key Data
| Open $22.33 | Day Range 21.89 - 23.44 |
| 52 Week Range N/A - N/A | Market Cap $811.63M |
| Shares Outstanding 36.58M | Public Float 17.47M |
| Beta -7.85 | Rev. Per Employee N/A |
| P/E Ratio N/A | EPS -$1.77 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 76.97K |
RAPP Performance
| 1 Week | 5.92% | ||
| 1 Month | -8.38% | ||
| 3 Months | -0.49% | ||
| 1 Year | N/A | ||
| 5 Years | N/A |
RAPP Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
4
Full Ratings ➔
About rapport therapeutics inc - RAPP
Rapport Therapeutics, Inc. engages in the discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. It develops the RAP (receptor associated proteins) technology platform. The company was founded by Steven M. Paul and David Bredt in February 2022 and is headquartered in Boston, MA.
RAPP At a Glance
Rapport Therapeutics, Inc.
1325 Boylston Street
Boston, Massachusetts 02215
| Phone | 1-857-321-8020 | Revenue | 0.00 | |
| Industry | Biotechnology | Net Income | -34,786,000.00 | |
| Sector | Health Technology | Employees | 58 | |
| Fiscal Year-end | 12 / 2024 | |||
| View SEC Filings |
RAPP Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | N/A |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | N/A |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | N/A |
RAPP Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -599,758.621 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
RAPP Liquidity
| Current Ratio | 17.139 |
| Quick Ratio | 17.139 |
| Cash Ratio | 16.763 |
RAPP Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -37.199 |
| Return on Equity | -43.361 |
| Return on Total Capital | -24.311 |
| Return on Invested Capital | -42.966 |
RAPP Capital Structure
| Total Debt to Total Equity | 1.523 |
| Total Debt to Total Capital | 1.50 |
| Total Debt to Total Assets | 1.381 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | 1.032 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Rapport Therapeutics Inc - RAPP
Collapse All in section
| All values USD millions. | 2022 | 2023 | 5-year trend | ||
|---|---|---|---|---|---|
Sales/Revenue
| - | - | - | - | - |
Sales Growth
| - | - | - | - | - |
Cost of Goods Sold (COGS) incl D&A
| - | - | 15.00K | 112.00K | - |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| - | - | 15.00K | 112.00K | - |
Depreciation
| - | - | 15.00K | 112.00K | - |
Amortization of Intangibles
| - | - | - | - | - |
COGS Growth
| - | - | - | +646.67% | - |
Gross Income
| - | - | (15.00K) | (112.00K) | - |
Gross Income Growth
| - | - | - | -646.67% | - |
Gross Profit Margin
| - | - | - | - | - |
| 2022 | 2023 | 5-year trend | |||
|---|---|---|---|---|---|
SG&A Expense
| - | - | 10.35M | 36.07M | - |
Research & Development
| - | - | 9.12M | 28.00M | - |
Other SG&A
| - | - | 1.24M | 8.07M | - |
SGA Growth
| - | - | - | +248.41% | - |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| - | - | - | 1.12M | - |
EBIT after Unusual Expense
| - | - | (10.37M) | (37.30M) | - |
Non Operating Income/Expense
| - | - | - | 2.53M | - |
Non-Operating Interest Income
| - | - | - | 2.53M | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| - | - | - | 285.00K | - |
Interest Expense Growth
| - | - | - | -100.00% | - |
Gross Interest Expense
| - | - | - | 285.00K | - |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| - | - | (10.65M) | (34.78M) | - |
Pretax Income Growth
| - | - | - | -226.47% | - |
Pretax Margin
| - | - | - | - | - |
Income Tax
| - | - | - | 10.00K | - |
Income Tax - Current - Domestic
| - | - | - | 10.00K | - |
Income Tax - Current - Foreign
| - | - | - | - | - |
Income Tax - Deferred - Domestic
| - | - | - | - | - |
Income Tax - Deferred - Foreign
| - | - | - | - | - |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| - | - | (10.65M) | (34.79M) | - |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| - | - | (10.65M) | (34.79M) | - |
Net Income Growth
| - | - | - | -226.57% | - |
Net Margin Growth
| - | - | - | - | - |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| - | - | (10.65M) | (34.79M) | - |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| - | - | (10.65M) | (34.79M) | - |
EPS (Basic)
| - | - | -0.2912 | -0.951 | - |
EPS (Basic) Growth
| - | - | - | -226.58% | - |
Basic Shares Outstanding
| - | - | 36.58M | 36.58M | - |
EPS (Diluted)
| - | - | -0.2912 | -0.951 | - |
EPS (Diluted) Growth
| - | - | - | -226.58% | - |
Diluted Shares Outstanding
| - | - | 36.58M | 36.58M | - |
EBITDA
| - | - | (10.35M) | (36.07M) | - |
EBITDA Growth
| - | - | - | -248.41% | - |
EBITDA Margin
| - | - | - | - | - |
Snapshot
| Average Recommendation | BUY | Average Target Price | 35.00 | |
| Number of Ratings | 4 | Current Quarters Estimate | -0.64 | |
| FY Report Date | 12 / 2024 | Current Year's Estimate | -5.754 | |
| Last Quarter’s Earnings | -0.50 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | N/A | Next Fiscal Year Estimate | -3.356 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 5 | 4 | 5 | 5 |
| Mean Estimate | -0.64 | -0.71 | -5.75 | -3.36 |
| High Estimates | -0.59 | -0.65 | -3.29 | -2.97 |
| Low Estimate | -0.70 | -0.79 | -13.97 | -3.70 |
| Coefficient of Variance | -6.15 | -8.13 | -79.93 | -9.86 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 4 | 4 | 3 |
| OVERWEIGHT | 0 | 0 | 0 |
| HOLD | 0 | 0 | 0 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Buy | Buy | Buy |
SEC Filings for Rapport Therapeutics Inc - RAPP
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Rapport Therapeutics Inc - RAPP
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Nov 8, 2024 | Paul M. Silva Director | 29,756 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Nov 8, 2024 | Robert J. Perez Director | 29,756 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Nov 8, 2024 | Ramiro Sánchez Director | 29,756 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Aug 20, 2024 | Sofinnova Investments, Inc. Director | 1,392,738 | Conversion of derivative security | 0.00 |
| Aug 20, 2024 | Sofinnova Investments, Inc. Director | 1,863,327 | Open market or private purchase of non-derivative security Non-derivative transaction at $17 per share | 31,676,559.00 |
| Aug 20, 2024 | Sofinnova Investments, Inc. Director | 18,641 | Open market or private purchase of non-derivative security Non-derivative transaction at $17 per share | 316,897.00 |
| Aug 20, 2024 | Sofinnova Investments, Inc. Director | N/A | Conversion of derivative security | 0.00 |
| Jul 4, 2024 | Crestline Management LP Director | 21,660 | Open market or private purchase of non-derivative security Non-derivative transaction at $23.08 per share | 499,912.80 |
| Jul 4, 2024 | Crestline Management LP Director | 39,661 | Open market or private purchase of non-derivative security Non-derivative transaction at $26.06 per share | 1,033,565.66 |
| Jul 4, 2024 | Crestline Management LP Director | 37,102 | Open market or private purchase of non-derivative security Non-derivative transaction at $25.02 per share | 928,292.04 |
| Jul 4, 2024 | Crestline Management LP Director | 32,558 | Open market or private purchase of non-derivative security Non-derivative transaction at $24.21 per share | 788,229.18 |
| Jul 4, 2024 | Crestline Management LP Director | 28,993 | Open market or private purchase of non-derivative security Non-derivative transaction at $23.08 per share | 669,158.44 |
| Jul 4, 2024 | Crestline Management LP Director | 33,565 | Open market or private purchase of non-derivative security Non-derivative transaction at $24.21 per share | 812,608.65 |
| Jul 4, 2024 | Crestline Management LP Director | 38,226 | Open market or private purchase of non-derivative security Non-derivative transaction at $25.02 per share | 956,414.52 |
| Jul 4, 2024 | Crestline Management LP Director | 40,851 | Open market or private purchase of non-derivative security Non-derivative transaction at $26.06 per share | 1,064,577.06 |
| Jul 4, 2024 | Crestline Management LP Director | 25,488 | Open market or private purchase of non-derivative security Non-derivative transaction at $24.21 per share | 617,064.48 |
| Jul 4, 2024 | Crestline Management LP Director | 30,366 | Open market or private purchase of non-derivative security Non-derivative transaction at $25.02 per share | 759,757.32 |
| Jul 4, 2024 | Crestline Management LP Director | 33,114 | Open market or private purchase of non-derivative security Non-derivative transaction at $26.06 per share | 862,950.84 |
| Jul 4, 2024 | Crestline Management LP Director | 29,908 | Open market or private purchase of non-derivative security Non-derivative transaction at $23.08 per share | 690,276.64 |
| Jun 21, 2024 | Third Rock Ventures LLC | N/A | Conversion of derivative security | 0.00 |